Zhang Qing, Dong Yi, Zhai Zhimin, Tao Qianshan
Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Transfus Med Hemother. 2023 Aug 22;51(1):55-60. doi: 10.1159/000531681. eCollection 2024 Feb.
Chimeric antigen receptor T (CAR-T) cell therapy is an effective bridging treatment for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in relapsed or refractory acute lymphoblastic leukemia (ALL). However, repetitive CAR-T cell therapy and allo-HSCT can only be performed in a few patients because of technical difficulties and patients' physical, economic, and social conditions.
A 23-year-old female patient with second relapsed B-cell ALL (B-ALL) underwent human-murine chimeric CD19 CAR-T cell therapy twice, human-murine chimeric CD22 CAR-T cell therapy once, and humanized CD19 CAR-T cell therapy once. Moreover, she was sequentially bridged to her mother donor allo-HSCT once and cousin donor allo-HSCT once.
Repetitive CAR-T cell therapy bridging to repetitive allo-HSCT is still a safe and active therapeutic strategy for patients with relapsed or refractory ALL.
嵌合抗原受体T（CAR-T）细胞疗法是复发或难治性急性淋巴细胞白血病（ALL）患者异基因造血干细胞移植（allo-HSCT）的一种有效过渡治疗方法。然而，由于技术难题以及患者的身体、经济和社会状况，重复进行CAR-T细胞疗法和allo-HSCT仅能在少数患者中实施。
一名23岁复发性B细胞ALL（B-ALL）女性患者接受了两次人鼠嵌合CD19 CAR-T细胞疗法、一次人鼠嵌合CD22 CAR-T细胞疗法和一次人源化CD19 CAR-T细胞疗法。此外，她先后接受了一次来自母亲供体的allo-HSCT和一次来自表亲供体的allo-HSCT。
对于复发或难治性ALL患者，重复CAR-T细胞疗法联合重复allo-HSCT仍是一种安全且有效的治疗策略。
